296:
approved
Illumina's plan, allowing Illumina to explore either a trade sale or a capital markets transaction (spin-off) to divest Grail. In May 2024, Illumina publicly filed a Form 10 registration statement with the U.S. SEC, a necessary step for a potential capital markets separation of Grail. If a capital markets transaction occurs, Illumina must capitalize Grail with around $ 1 billion to fund 2.5 years of operations per the EC's divestment plan. The spinoff was completed in June 2024, with Grail trading on the
40:
192:(also called multi-cancer early detection test) was launched in June 2021 and is called the Galleri test. Promoted as groundbreaking, the test performed poorly in testing and Grail has subsequently faced discontent and legal action from investors claiming they have been misled about the test's potential.
200:
Illumina's own research showed that repeatedly sequencing DNA in the bloodstream made it possible to detect floating bits of DNA from cancer cells more accurately. It initially aimed to recruit greater than 100,000 people into its clinical trials in order to accumulate the sizeable data required to
295:
ordered Grail to be divested from
Illumina within the next twelve months. The European Commission (EC) has since approved Illumina's divestment plan for separating from Grail. Illumina has set a goal of finalizing the divestment terms by the end of the second quarter of 2024. In April 2024, the EC
220:
Despite Grail promoting the test as a "groundbreaking and potentially life-saving advance", the results of early trials were poor. A subsequent large-scale NHS England trial has been described by experts as overhyped and unethical. Grail is facing discontent and legal action from investors who
283:
In June 2023, Grail disclosed that letters were mailed to 408 patients incorrectly informing them that they may have cancer. The company blamed the incident on PWNHealth, saying that it was due to a software configuration issue, not due to incorrect
Galleri test results.
287:
In July 2023, it was reported that three separate lawsuits were filed against Grail by former female employees; the allegations included that Grail created a "frat house” culture and a “sexually charged, hostile work environment”.
253:, he correctly predicted how DNA sequencing technology would make it possible to detect evidence of a tumor from a blood sample. He also joined Grail's board of directors. According to
217:
for early cancer the
Galleri test or the Galleri multi-cancer early detection (MCED) test, one of three multi-cancer screening tests which was under investigation as of November 2020.
885:
765:
321:
977:
941:
464:
185:
started as a startup seeking to develop an early cancer screening test for people who do not have symptoms. Grail was spun-out from
Illumina on June 24, 2024.
1049:
1089:
1109:
816:
1094:
1074:
1064:
791:
620:
713:
959:
1099:
435:
McCartney M, Cohen D (August 7, 2024). "Galleri promises to detect multiple cancers—but new evidence casts doubt on this much hyped blood test".
923:
1104:
1059:
738:
1119:
1054:
844:
667:
500:
375:
522:
392:
344:
266:
1069:
1026:
1114:
1084:
1079:
246:
280:. In September 2022, an administrative judge ruled against the FTC's position on antitrust grounds.
273:
904:
866:
685:
262:
In
September 2020, Illumina announced an agreement to purchase Grail outright for $ 7.1 billion.
850:
17:
174:
107:
978:"Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL"
657:
490:
363:
170:
843:
8:
626:
292:
241:
machines that scientists use to study human biology and diagnose rare genetic diseases.
595:
560:
577:
817:"FTC Challenges Illumina's Proposed Acquisition of Cancer Detection Test Maker Grail"
792:"FTC Seeks to Block Illumina's $ 7.1 Billion Acquisition of Life Sciences Firm Grail"
663:
631:
600:
582:
541:
496:
412:
404:
371:
202:
68:
1021:
1016:
590:
572:
531:
440:
242:
908:
277:
230:
238:
234:
182:
50:
1043:
635:
586:
536:
517:
408:
214:
189:
78:
58:
942:"Illumina's planned divestment of GRAIL approved by the European Commission"
766:"Sequencing Firm Illumina to Pay $ 7.1 Billion for Liquid-Biopsy Firm Grail"
621:"Sequencing Firm Illumina to Pay $ 7.1 Billion for Liquid-Biopsy Firm Grail"
604:
545:
416:
130:
1011:
886:"Grail says about 400 patients incorrectly informed they may have cancer"
265:
On
November 27, 2020, Grail announced a commercial partnership with the
1031:
300:
with ticker symbol GRAL and
Illumina retaining a 14.5% share of Grail.
178:
518:"Novel blood-based early cancer detection: diagnostics in development"
465:"Company Will Raise $ 1 Billion To Create Blood Test To Detect Cancer"
444:
492:
MoneyBall
Medicine: Thriving in the New Data-Driven Healthcare Market
488:
322:"Grail bets big on flagship cancer test after spin-off from Illumina"
867:"More than 400 Grail patients incorrectly told they may have cancer"
245:, then chief medical officer at Illumina and former director of the
905:"Grail sued by three female ex-employees over 'toxic work culture'"
739:"Illumina Launches GRAIL, Focused on Blood-Based Cancer Screening"
927:
368:
Managing
Biotechnology: From Science to Market in the Digital Age
561:"Cancer detection: the quest for a single liquid biopsy for all"
229:
Grail began as a San Francisco biotechnology and pharmaceutical
297:
255:
64:
686:"Illumina agrees $ 8bn deal for cancer screening group Grail"
489:
Harry Glorikian; Malorye Allison Branca (November 20, 2017).
39:
924:"Illumina ordered by EU antitrust regulators to sell Grail"
659:
Management and Technological Challenges in the Digital Age
960:"Statement Regarding Illumina's Decision to Divest Grail"
790:
Kendall, Brent; Rockoff, Jonathan D. (March 31, 2021).
683:
Kuchler, Hannah; Aliaj, Ortenca (September 21, 2020).
259:
in 2017, 20% of Grail's profits are kept by Illumina.
845:"Illumina Wins Case Against FTC on Grail Acquisition"
361:
269:(NHS), to trial the Galleri test, reporting in 2026.
221:
suspect that its cancer testing claims misled them.
1000:
155:
558:
355:
249:, advocated for the new business. According to the
684:
619:
482:
714:"Biotech's elder statesman is still going strong"
1041:
743:GEN - Genetic Engineering and Biotechnology News
655:
676:
649:
789:
434:
1050:Pharmaceutical companies of the United States
903:Smyth, Jamie; Kinder, Tabby (July 13, 2023).
552:
1090:Biotechnology companies of the United States
682:
656:Novo Melo, Pedro; Machado, Carolina (2018).
345:"This Blood Test Targets 50 Types of Cancer"
1110:Biotechnology companies established in 2015
902:
764:Rockoff, Jonathan D. (September 21, 2020).
618:Rockoff, Jonathan D. (September 21, 2020).
362:Simon, Francoise; Glen Giovannetti (2017).
342:
319:
864:
823:. Federal Trade Commission. March 30, 2021
495:. Taylor & Francis. pp. 109–110.
393:"Galleri Test for the Detection of Cancer"
38:
1095:Health care companies established in 2015
1075:Health care companies based in California
1065:Companies based in Menlo Park, California
865:Smyth, Jamie; Smith, Ian (June 2, 2023).
594:
576:
535:
315:
313:
237:of San Diego, which produces most of the
458:
456:
454:
763:
617:
611:
509:
390:
364:"1. Digital evolution of biotechnology"
14:
1100:American companies established in 2015
1042:
841:
430:
428:
426:
310:
883:
711:
451:
370:. John Wiley & Sons. p. 21.
921:
559:The Lancet Oncology (June 1, 2020).
523:The American Journal of Managed Care
516:Beer, Tomasz M. (November 1, 2020).
515:
391:Pyzocha, Natasha J. (October 2022).
343:Bedingfield, Will (March 30, 2023).
320:Steenhuysen, Julie (June 24, 2024).
842:Loftus, Peter (September 1, 2022).
423:
24:
922:Chee, Foo Yun (October 12, 2023).
462:
233:in 2015, the parent company being
25:
1131:
1105:2015 establishments in California
992:
267:National Health Service (England)
144:
1060:American corporate subsidiaries
970:
952:
934:
915:
896:
877:
858:
835:
809:
783:
757:
731:
705:
208:
1120:Companies listed on the Nasdaq
884:Sunny, Mariam (June 2, 2023).
384:
336:
13:
1:
1055:2021 mergers and acquisitions
578:10.1016/S1470-2045(20)30033-4
303:
195:
718:San Francisco Business Times
251:San Francisco Business Times
27:American health care company
7:
712:Leuty, Ron (May 27, 2021).
10:
1136:
662:. CRC Press. p. 157.
224:
90:; 9 years ago
1007:Business data for GRAIL:
397:American Family Physician
247:National Cancer Institute
150:
140:
118:
102:
84:
74:
56:
46:
37:
964:Federal Trade Commission
537:10.37765/ajmc.2020.88533
276:(FTC) sued to block the
274:Federal Trade Commission
851:The Wall Street Journal
1070:Life sciences industry
177:. It was previously a
175:Menlo Park, California
108:Menlo Park, California
291:In October 2023, the
201:detect and interpret
171:biotechnology company
966:. December 18, 2023.
1115:Corporate spin-offs
984:. February 1, 2019.
796:Wall Street Journal
770:Wall Street Journal
627:Wall Street Journal
565:The Lancet Oncology
293:European Commission
272:In March 2021, the
133:(president, Europe)
34:
1085:Genomics companies
745:. January 11, 2016
32:
693:. Financial Times
669:978-0-429-81623-9
530:(14): S292–S299.
502:978-1-351-98433-1
463:Herper, Matthew.
445:10.1136/bmj.q1706
439:(Investigation).
377:978-1-119-21617-9
203:cancer biomarkers
164:
163:
16:(Redirected from
1127:
1080:Medical genetics
1004:
1003:
1001:Official website
986:
985:
974:
968:
967:
956:
950:
949:
938:
932:
931:
919:
913:
912:
900:
894:
893:
881:
875:
874:
862:
856:
855:
847:
839:
833:
832:
830:
828:
813:
807:
806:
804:
802:
787:
781:
780:
778:
776:
761:
755:
754:
752:
750:
735:
729:
728:
726:
724:
709:
703:
702:
700:
698:
688:
680:
674:
673:
653:
647:
646:
644:
642:
623:
615:
609:
608:
598:
580:
556:
550:
549:
539:
513:
507:
506:
486:
480:
479:
477:
475:
460:
449:
448:
432:
421:
420:
388:
382:
381:
359:
353:
352:
340:
334:
333:
331:
329:
317:
243:Richard Klausner
213:Grail calls its
160:
157:
127:Bob Ragusa (CEO)
98:
96:
91:
42:
35:
31:
21:
1135:
1134:
1130:
1129:
1128:
1126:
1125:
1124:
1040:
1039:
1036:
999:
998:
995:
990:
989:
976:
975:
971:
958:
957:
953:
940:
939:
935:
920:
916:
909:Financial Times
901:
897:
882:
878:
871:Financial Times
863:
859:
840:
836:
826:
824:
815:
814:
810:
800:
798:
788:
784:
774:
772:
762:
758:
748:
746:
737:
736:
732:
722:
720:
710:
706:
696:
694:
681:
677:
670:
654:
650:
640:
638:
616:
612:
557:
553:
514:
510:
503:
487:
483:
473:
471:
461:
452:
433:
424:
389:
385:
378:
360:
356:
341:
337:
327:
325:
318:
311:
306:
278:vertical merger
231:startup company
227:
211:
198:
169:is an American
154:
136:
121:
114:
110:
94:
92:
89:
61:
28:
23:
22:
15:
12:
11:
5:
1133:
1123:
1122:
1117:
1112:
1107:
1102:
1097:
1092:
1087:
1082:
1077:
1072:
1067:
1062:
1057:
1052:
1038:
1037:
1035:
1034:
1029:
1024:
1019:
1014:
1008:
1005:
994:
993:External links
991:
988:
987:
969:
951:
948:. May 6, 2024.
933:
914:
895:
876:
857:
834:
808:
782:
756:
730:
704:
675:
668:
648:
610:
551:
508:
501:
481:
450:
422:
403:(4): 459–460.
383:
376:
354:
335:
308:
307:
305:
302:
239:DNA sequencing
226:
223:
210:
207:
197:
194:
162:
161:
152:
148:
147:
142:
138:
137:
135:
134:
128:
124:
122:
119:
116:
115:
112:
106:
104:
100:
99:
86:
82:
81:
76:
72:
71:
62:
57:
54:
53:
48:
44:
43:
26:
9:
6:
4:
3:
2:
1132:
1121:
1118:
1116:
1113:
1111:
1108:
1106:
1103:
1101:
1098:
1096:
1093:
1091:
1088:
1086:
1083:
1081:
1078:
1076:
1073:
1071:
1068:
1066:
1063:
1061:
1058:
1056:
1053:
1051:
1048:
1047:
1045:
1033:
1030:
1028:
1025:
1023:
1020:
1018:
1015:
1013:
1010:
1009:
1006:
1002:
997:
996:
983:
979:
973:
965:
961:
955:
947:
943:
937:
929:
925:
918:
910:
906:
899:
891:
887:
880:
872:
868:
861:
853:
852:
846:
838:
822:
818:
812:
797:
793:
786:
771:
767:
760:
744:
740:
734:
719:
715:
708:
692:
687:
679:
671:
665:
661:
660:
652:
637:
633:
629:
628:
622:
614:
606:
602:
597:
592:
588:
584:
579:
574:
570:
566:
562:
555:
547:
543:
538:
533:
529:
525:
524:
519:
512:
504:
498:
494:
493:
485:
470:
466:
459:
457:
455:
446:
442:
438:
431:
429:
427:
418:
414:
410:
406:
402:
398:
394:
387:
379:
373:
369:
365:
358:
350:
346:
339:
328:September 12,
323:
316:
314:
309:
301:
299:
294:
289:
285:
281:
279:
275:
270:
268:
263:
260:
258:
257:
252:
248:
244:
240:
236:
232:
222:
218:
216:
215:liquid biopsy
206:
204:
193:
191:
190:liquid biopsy
186:
184:
180:
176:
172:
168:
159:
153:
149:
146:
143:
139:
132:
129:
126:
125:
123:
117:
113:United States
109:
105:
101:
87:
83:
80:
79:Biotechnology
77:
73:
70:
66:
63:
60:
55:
52:
49:
45:
41:
36:
30:
19:
981:
972:
963:
954:
945:
936:
917:
898:
889:
879:
870:
860:
849:
837:
825:. Retrieved
820:
811:
799:. Retrieved
795:
785:
773:. Retrieved
769:
759:
747:. Retrieved
742:
733:
721:. Retrieved
717:
707:
695:. Retrieved
690:
678:
658:
651:
641:November 27,
639:. Retrieved
625:
613:
568:
564:
554:
527:
521:
511:
491:
484:
474:November 27,
472:. Retrieved
468:
436:
400:
396:
386:
367:
357:
348:
338:
326:. Retrieved
290:
286:
282:
271:
264:
261:
254:
250:
228:
219:
212:
209:Galleri test
199:
187:
166:
165:
145:Galleri test
131:Harpal Kumar
103:Headquarters
47:Company type
29:
1027:SEC filings
697:December 1,
167:GRAIL, Inc.
33:GRAIL, Inc.
1044:Categories
571:(6): 733.
304:References
196:Activities
179:subsidiary
120:Key people
1012:Bloomberg
827:March 31,
801:March 31,
775:March 31,
636:0099-9660
587:1470-2045
409:1532-0650
324:. Reuters
173:based in
59:Traded as
982:Illumina
946:Illumina
749:June 25,
723:June 25,
605:32502435
546:33200893
417:36260909
235:Illumina
183:Illumina
141:Products
75:Industry
1022:Reuters
928:Reuters
890:Reuters
821:FTC.gov
596:7266566
225:History
151:Website
93: (
85:Founded
67::
18:Galleri
1032:Yahoo!
1017:Google
691:ft.com
666:
634:
603:
593:
585:
544:
499:
469:Forbes
415:
407:
374:
298:Nasdaq
256:Forbes
188:Their
65:Nasdaq
51:Public
349:Wired
156:grail
829:2021
803:2021
777:2021
751:2023
725:2023
699:2020
664:ISBN
643:2020
632:ISSN
601:PMID
583:ISSN
542:PMID
497:ISBN
476:2020
413:PMID
405:ISSN
372:ISBN
330:2024
158:.com
95:2015
88:2015
69:GRAL
591:PMC
573:doi
532:doi
441:doi
437:BMJ
401:106
181:of
1046::
980:.
962:.
944:.
926:.
907:.
888:.
869:.
848:.
819:.
794:.
768:.
741:.
716:.
689:.
630:.
624:.
599:.
589:.
581:.
569:21
567:.
563:.
540:.
528:26
526:.
520:.
467:.
453:^
425:^
411:.
399:.
395:.
366:.
347:.
312:^
205:.
111:,
930:.
911:.
892:.
873:.
854:.
831:.
805:.
779:.
753:.
727:.
701:.
672:.
645:.
607:.
575::
548:.
534::
505:.
478:.
447:.
443::
419:.
380:.
351:.
332:.
97:)
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
